Orca-T Shows Promise in Intermediate-/High-Risk MDS

The stem cell thrapy, Orca-T led to promising relapse-free and overall survival rates in patients with intermediate- to high-risk myelodysplastic syndrome.

Related Keywords

Oregon ,United States ,American ,Arpita Gandhi ,American Society Of Hematology Annual Meeting ,Molecular International Prognostic Scoring System ,Oregon Health ,Division Of Hematology Medical Oncology ,Science University ,International Expert Panel ,School Of Medicine ,Hematology Annual ,Medical Oncology ,Expert Panel ,News ,Conference ,Mds ,